Fundación MEDINA (MEDicamentos INnovadores en Andalucía) is one of the high throughput screening centers of EU-OPENSCREEN-ERIC, the new infrastructure officially announced on March 21, 2018 by the European Official Journal of the EU as European Research Infrastructure...
MEDINA is leader in Drug Discovery from Microbial Natural Product Libraries and internal High Throughput Screening (HTS) programs are focused on strategic therapeutic areas: Infectious and Parasitic Diseases, Oncology and Neurodegeneration.
We are partners in European research networks and consortia in diverse areas of drug discovery and applied biotechnology.
MEDINA offers Contract Research services for Drug Discovery and other high value biotechnology areas to academic research and industrial organizations.
MEDINA discovers bio-active molecules, drug leads for unmet medical needs and high value biotechnological products.
We are exclusive owners of one of the world´s largest Microbial Collections (190,000 microbial strains), and Natural Products Libraries (over 135,000 extracts & fractions).
SUBSCRIBE TO OUR NEWSLETTER
28th ECCMID European Congress of Clinical Microbiology and Infectious Diseases, 21-24 April, Madrid – Spain
MEDINA has attended one more year ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) in Madrid. Dr. Olga Genilloud presented the Discovery of the novel glycosylated lanthipeptide MDN-0207, a new antibiotic with unprecedented chemical features...
Systemic blockade of LPA1/3 lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior, Neuropharmacology
MEDINA has participated in the paper about ki16425 modulation of the effects of ethanol on the brain and behavior, published in Neuropharmacology. This is a broad and complete paper at the technical and experimental level, including numerous data and procedures, part...